Regencell Bioscience Class Action Reminder for Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notice: Robbins LLP reminds all investors who purchased Regencell Bioscience (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect shareholder rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and potential regulatory scrutiny and legal repercussions.
- Stock Price Volatility: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice due to market volatility, leading to a $3.09 drop in share price, or 18.56%, closing at $13.56 on November 3, 2025, indicating market concerns about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by June 23, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members eligible for recovery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Bioscience Class Action Reminder for Shareholders
- Class Action Notice: Robbins LLP reminds all investors who purchased Regencell Bioscience (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect shareholder rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and potential regulatory scrutiny and legal repercussions.
- Stock Price Volatility: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice due to market volatility, leading to a $3.09 drop in share price, or 18.56%, closing at $13.56 on November 3, 2025, indicating market concerns about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by June 23, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members eligible for recovery.
See More
Regencell Faces Securities Class Action Amid $14 Billion Valuation Concerns
- Market Manipulation Risk: Regencell disclosed a DOJ subpoena on October 31, 2025, revealing that the company's stock price volatility was unrelated to its fundamentals, leading to an 18.56% drop in share price post-announcement.
- Insider Knowledge vs. Public Statements: The lawsuit alleges that Regencell's leadership was aware of the stock's vulnerability to manipulation throughout the class period but failed to disclose this critical information to shareholders, instead masking potential regulatory risks with vague warnings.
- Shareholder Value Erosion: With Yat-Gai Au owning 88.6% of the shares, significant price movements directly impacted his net worth, creating a strong incentive to remain vigilant about trading irregularities, which further exacerbated the concealment from investors.
- Potential Legal Consequences: The lawsuit indicates that Regencell may face fines, penalties, and other administrative proceedings, urging investors to submit claims by June 23, 2026, to protect their rights and recover losses.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell made false and misleading statements regarding its business and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny and legal repercussions.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs, highlighting the importance of this case in protecting investor rights and potentially influencing future investment decisions.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, indicating its expertise and influence in investor protection and securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and potentially triggering regulatory scrutiny that could harm its reputation and financial stability.
- SES AI Growth Prospects Questioned: SES AI faces allegations of overstating its business prospects from January 2025 to March 2026, as deals with companies lacking operations failed to yield expected revenues, leading to lower-than-expected revenue guidance for 2026, which undermines investor confidence.
- FS KKR Capital Overestimation: From May 2024 to February 2026, FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts, which could damage investor trust in the company's financial health and affect its future financing capabilities.
- Graphic Packaging Operational Issues: During the period from February 2025 to February 2026, Graphic Packaging is alleged to have downplayed significant inventory management issues and reduced demand, resulting in a material negative impact on its financial results, which could affect its market competitiveness and investor trust.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: The Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will forfeit their rights to compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for victims and encouraging broader participation in the lawsuit.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation during the class period, exposing investors to significant financial risks and subjecting the company to regulatory scrutiny and potential legal liabilities, which could adversely affect its future market performance.
- Law Firm's Strength: The Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource advantages in handling such cases.
See More
Regencell Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 23, 2026, to participate in the class action against Regencell, which involves those who purchased the company's securities between October 28, 2024, and October 31, 2025.
- Market Volatility Impact: On October 31, 2025, Regencell received a subpoena from the U.S. Department of Justice due to market volatility, resulting in a stock price drop of $3.09, or 18.56%, on November 3, 2025, which adversely affected investors' financial positions.
- Expected Legal Costs: The company anticipates incurring significant legal fees and other expenses related to the investigation, potentially requiring payments exceeding its insurance coverage, which could strain its financial health.
- False Statements Allegations: The class action alleges that the company failed to disclose risks of market manipulation and regulatory scrutiny during the class period, exposing investors to substantial financial risks and harming their interests.
See More
Regencell Bioscience Class Action Reminder for Shareholders
- Class Action Notice: Robbins LLP reminds all investors who purchased Regencell Bioscience (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect shareholder rights and seek compensation.
- Market Manipulation Allegations: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and potential regulatory scrutiny and legal repercussions.
- Stock Price Volatility: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice due to market volatility, leading to a $3.09 drop in share price, or 18.56%, closing at $13.56 on November 3, 2025, indicating market concerns about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by June 23, 2026, to apply as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members eligible for recovery.
See More
Regencell Faces Securities Class Action Amid $14 Billion Valuation Concerns
- Market Manipulation Risk: Regencell disclosed a DOJ subpoena on October 31, 2025, revealing that the company's stock price volatility was unrelated to its fundamentals, leading to an 18.56% drop in share price post-announcement.
- Insider Knowledge vs. Public Statements: The lawsuit alleges that Regencell's leadership was aware of the stock's vulnerability to manipulation throughout the class period but failed to disclose this critical information to shareholders, instead masking potential regulatory risks with vague warnings.
- Shareholder Value Erosion: With Yat-Gai Au owning 88.6% of the shares, significant price movements directly impacted his net worth, creating a strong incentive to remain vigilant about trading irregularities, which further exacerbated the concealment from investors.
- Potential Legal Consequences: The lawsuit indicates that Regencell may face fines, penalties, and other administrative proceedings, urging investors to submit claims by June 23, 2026, to protect their rights and recover losses.
See More
Regencell Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell made false and misleading statements regarding its business and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny and legal repercussions.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs, highlighting the importance of this case in protecting investor rights and potentially influencing future investment decisions.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, indicating its expertise and influence in investor protection and securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Regencell Bioscience Lawsuit: During the period from October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and potentially triggering regulatory scrutiny that could harm its reputation and financial stability.
- SES AI Growth Prospects Questioned: SES AI faces allegations of overstating its business prospects from January 2025 to March 2026, as deals with companies lacking operations failed to yield expected revenues, leading to lower-than-expected revenue guidance for 2026, which undermines investor confidence.
- FS KKR Capital Overestimation: From May 2024 to February 2026, FS KKR is accused of exaggerating the effectiveness of its portfolio restructuring efforts, which could damage investor trust in the company's financial health and affect its future financing capabilities.
- Graphic Packaging Operational Issues: During the period from February 2025 to February 2026, Graphic Packaging is alleged to have downplayed significant inventory management issues and reduced demand, resulting in a material negative impact on its financial results, which could affect its market competitiveness and investor trust.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: The Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action, as those who do not will forfeit their rights to compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for victims and encouraging broader participation in the lawsuit.
- Legal Risks Exposed: The lawsuit alleges that Regencell failed to disclose vulnerabilities to market manipulation during the class period, exposing investors to significant financial risks and subjecting the company to regulatory scrutiny and potential legal liabilities, which could adversely affect its future market performance.
- Law Firm's Strength: The Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource advantages in handling such cases.
See More
Regencell Investors Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by June 23, 2026, to participate in the class action against Regencell, which involves those who purchased the company's securities between October 28, 2024, and October 31, 2025.
- Market Volatility Impact: On October 31, 2025, Regencell received a subpoena from the U.S. Department of Justice due to market volatility, resulting in a stock price drop of $3.09, or 18.56%, on November 3, 2025, which adversely affected investors' financial positions.
- Expected Legal Costs: The company anticipates incurring significant legal fees and other expenses related to the investigation, potentially requiring payments exceeding its insurance coverage, which could strain its financial health.
- False Statements Allegations: The class action alleges that the company failed to disclose risks of market manipulation and regulatory scrutiny during the class period, exposing investors to substantial financial risks and harming their interests.
See More
